SciBrunch Therapeutics Co., Ltd.

SciBrunch Therapeutics Co., Ltd. is a clinical-stage biotechnology company headquartered in Shanghai, China, focused on the discovery and development of differentiated small-molecule anti-tumor drugs through iterative innovation in oncology.

Established in 2024, the company targets clinically validated pathways with an emphasis on hard-to-treat cancers such as pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). Its pipeline features SPR1020, a highly selective, brain-penetrant PARP1 inhibitor in Phase I/II trials for advanced solid tumors, and SPR2015, an oral KRAS G12D (ON) molecular glue inhibitor exclusively licensed to MSD (Merck & Co.) in September 2026 for up to $2.53 billion in total value including a $400 million upfront payment.

The company operates from its base in Shanghai with global development ambitions and is privately held and venture-backed. It has raised approximately $65 million through an angel round in 2025 and a Pre-A round in early 2026, supported by investors including Hankang Capital, BioTrack Capital, HighLight Capital, InnoPinnacle Fund, and others.

Led by founders Tao Hu, PhD (Chairman and CEO) and Yang Zhang, PhD (CSO), who bring experience from WuXi AppTec, Merck, and Amgen, SciBrunch positions itself as an emerging player in precision oncology, advancing additional RAS pathway programs and other discovery-stage assets.